1-11 of 11
Marion Wiesmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201

Sébastien Jeay, Stéphane Ferretti, Philipp Holzer, Jeanette Fuchs, Emilie A. Chapeau, Markus Wartmann, Dario Sterker, Vincent Romanet, Masato Murakami, Grainne Kerr, Eric Y. Durand, Swann Gaulis, Marta Cortes-Cros, Stephan Ruetz, Therese-Marie Stachyra, Joerg Kallen, Pascal Furet, Jens Würthner, Nelson Guerreiro, Ensar Halilovic, Astrid Jullion, Audrey Kauffmann, Emil Kuriakose, Marion Wiesmann, Michael R. Jensen, Francesco Hofmann, William R. Sellers
Journal: Cancer Research
Series: Author Choice
Cancer Res (2018) 78 (21): 6257–6267.
https://doi.org/10.1158/0008-5472.CAN-18-0338
Published: 01 November 2018
View article titled, Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201
Open the PDF for Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201 in another window
Includes: Supplementary data
Journal Articles

Abstract 1224: Insights into the mechanism of action of NVP-HDM201, a differentiated and versatile Next-Generation small-molecule inhibitor of Mdm2, under evaluation in phase I clinical trials

Stéphane Ferretti, Ramona Rebmann, Marjorie Berger, Francesca Santacroce, Geneviève Albrecht, Kerstin Pollehn, Dario Sterker, Markus Wartmann, Andreas Hueber, Marion Wiesmann, Michael R. Jensen, Francesco Hofmann, William R. Sellers, Philipp Holzer, Sébastien Jeay
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 1224.
https://doi.org/10.1158/1538-7445.AM2016-1224
Published: 15 July 2016
View article titled, Abstract 1224: Insights into the mechanism of action of NVP-HDM201, a differentiated and versatile Next-Generation small-molecule inhibitor of Mdm2, under evaluation in phase I clinical trials
Journal Articles

Abstract 2909: A gene signature composed of 13 p53 target genes predicts for response to NVP-CGM097, a novel p53-Mdm2 inhibitor, in cell lines and in human primary tumor xenograft models

Sebastien Jeay, Swann Gaulis, Stéphane Ferretti, Geneviève Albrecht, Louise Barys, Daniel Guthy, Ensar Halilovic, Moriko Ito, Masato Murakami, Astrid Pornon, Stephan Ruetz, Kavitha Venkatesan, Jianjun Yu, Michael Jensen, Marion Wiesmann, Jens Wuerthner, Diana Graus-Porta
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 2909.
https://doi.org/10.1158/1538-7445.AM2014-2909
Published: 01 October 2014
View article titled, Abstract 2909: A gene signature composed of 13 p53 target genes predicts for response to NVP-CGM097, a novel p53-Mdm2 inhibitor, in cell lines and in human primary tumor xenograft models
Journal Articles

Abstract 1797: Discovery of NVP-CGM097, a highly potent and optimized small molecule inhibitor of Mdm2 under evaluation in a Phase I clinical trial

Sebastien Jeay, Joerg Berghausen, Nicole Buschmann, Patrick Chène, Robert Cozens, Dirk Erdmann, Stéphane Ferretti, Pascal Furet, Tobias Gabriel, François Gessier, Diana Graus-Porta, Francesco Hofmann, Philipp Holzer, Moriko Ito, Edgar Jacoby, Michael Jensen, Joerg Kallen, Marc Lang, Joanna Lisztwan, Masato Murakami, Carole Pissot-Soldermann, Stephan Ruetz, Caroline Rynn, Dario Sterker, Stefan Stutz, Thérèse Valat, Marion Wiesmann, Keiichi Masuya
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 1797.
https://doi.org/10.1158/1538-7445.AM2014-1797
Published: 01 October 2014
View article titled, Abstract 1797: Discovery of NVP-CGM097, a highly potent and optimized small molecule inhibitor of Mdm2 under evaluation in a Phase I clinical trial
Journal Articles

Abstract 5466: The Mdm2 inhibitor, NVP-CGM097, in combination with the BRAF inhibitor NVP-LGX818 elicits synergistic antitumor effects in melanoma

Hui Qin Wang, Matthew Zubrowski, Erling Emerson, Elina Pradhan, Sébastien Jeay, Marion Wiesmann, Giordano Caponigro, Jens Wuerthner, Robert Schlegel, Z. Alexander Cao, Alan Huang, Ensar Halilovic
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 5466.
https://doi.org/10.1158/1538-7445.AM2014-5466
Published: 01 October 2014
View article titled, Abstract 5466: The Mdm2 inhibitor, NVP-CGM097, in combination with the BRAF inhibitor NVP-LGX818 elicits synergistic antitumor effects in melanoma
Journal Articles

Abstract 2058: Systematic evaluation of drug combinations in vitro and in vivo.

Marion Wiesmann, Mark Stump, Giordano Caponigro, David Duhl, Brant Firestone, Tom Gesner, Bjoern Gruenenfelder, Daniel Alexander Guthy, Jocelyn Holash, Fred King, Joseph Lehar, Christophe Leroy, Manway Liu, Lilli Petruzelli, Dale Porter, Paul McSheehy, Daniel Menezes, Anupama Reddy, Johannes Roesel, Christian Schnell, Timothy R. Smith, Markus Wartmann
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 2058.
https://doi.org/10.1158/1538-7445.AM2013-2058
Published: 15 April 2013
View article titled, Abstract 2058: Systematic evaluation of drug combinations <em>in vitro</em> and <em>in vivo</em>.
Journal Articles

Abstract 4498: Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials

charles F. Voliva, Sabina Pecchi, Matthew Burger, Tobi Nagel, Christian Schnell, christine Fritsch, saskia Brachmann, Daniel Menezes, Mark Knapp, Kevin Shoemaker, Marion Wiesmann, kay Huh, Isabel Zaror, Marion Dorsch, William R. Sellers, Carlos Garcia-Echeverria, Michel Maira
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 4498.
https://doi.org/10.1158/1538-7445.AM10-4498
Published: 15 April 2010
View article titled, Abstract 4498: Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials
Journal Articles

Abstract 4497: NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials, shows significant antitumor activity in xenograft and primary tumor models

Michel Maira, Daniel Menezes, Sabina Pecchi, Kevin Shoemaker, Matthew Burger, christian Schnell, christine Fritsch, Saskia Brachmann, Tobi Nagel, William R. Sellers, Carlos Garcia-Echeverria, Marion Wiesmann, charles F. Voliva
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 4497.
https://doi.org/10.1158/1538-7445.AM10-4497
Published: 15 April 2010
View article titled, Abstract 4497: NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials, shows significant antitumor activity in xenograft and primary tumor models
Journal Articles

Abstract 3629: BLZ945, a selective c-fms (CSF-1R) kinase inhibitor for the suppression of tumor-induced osteolytic lesions in bone

Marion Wiesmann, Dylan L. Daniel, Nancy Pryer, James Sutton, Victoria Sung, Tao Wang, Ursula Jeffry, Yoko Oei, Susan Kaufman, William Lenahan, Isabelle Lee, Kay Huh, Janet Sim
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 3629.
https://doi.org/10.1158/1538-7445.AM10-3629
Published: 15 April 2010
View article titled, Abstract 3629: BLZ945, a selective c-fms (CSF-1R) kinase inhibitor for the suppression of tumor-induced osteolytic lesions in bone
Journal Articles

Pre-clinical studies of CHIR258, a small molecule inhibitor that targets FGFR3, for the treatment of t(4;14) multiple myeloma

Suzanne Trudel, Zhi Hua Li, Ellen Wei, Marion Wiesmann, Gena Lapointe, Isabelle Lee, Carla Heise, Alex Harris, Keith A. Stewart
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 1300.
Published: 01 April 2004
View article titled, Pre-clinical studies of CHIR258, a small molecule inhibitor that targets FGFR3, for the treatment of t(4;14) multiple myeloma
Journal Articles

β-Catenin Regulates Vascular Endothelial Growth Factor Expression in Colon Cancer

Vijay Easwaran, Sang H. Lee, Landon Inge, Lida Guo, Cheryl Goldbeck, Evelyn Garrett, Marion Wiesmann, Pablo D. Garcia, John H. Fuller, Vivien Chan, Filippo Randazzo, Robert Gundel, Robert S. Warren, Jaime Escobedo, Sharon L. Aukerman, Robert N. Taylor, Wendy J. Fantl
Journal: Cancer Research
Cancer Res (2003) 63 (12): 3145–3153.
Published: 15 June 2003
View article titled, β-Catenin Regulates Vascular Endothelial Growth Factor Expression in Colon Cancer
Open the PDF for β-Catenin Regulates Vascular Endothelial Growth Factor Expression in Colon Cancer in another window